Alternate-day fasting exacerbates doxorubicin cardiotoxicity in cancer chemotherapy

Huachun Pan; Shumin Yang; Wenke Cheng; Qiang Cai; Quazi T H Shubhra

doi:10.1016/j.tem.2023.05.003

Alternate-day fasting exacerbates doxorubicin cardiotoxicity in cancer chemotherapy

Trends Endocrinol Metab. 2023 Jul;34(7):392-394. doi: 10.1016/j.tem.2023.05.003. Epub 2023 May 26.

Authors

Huachun Pan¹, Shumin Yang¹, Wenke Cheng², Qiang Cai³, Quazi T H Shubhra⁴

Affiliations

¹ College of Animal Science and Technology, Huazhong Agricultural University, Wuhan 430070, China.
² Medical Faculty, University of Leipzig, Leipzig 04103, Germany.
³ Department of Neurosurgery, Renmin Hospital of Wuhan University, Wuhan 430060, Hubei Province, China.
⁴ Department of Neurosurgery, Renmin Hospital of Wuhan University, Wuhan 430060, Hubei Province, China; Institute of Chemistry, University of Silesia in Katowice, 41-500 Chorzów, Poland. Electronic address: shubhro.du@gmail.com.

PMID: 37246117
DOI: 10.1016/j.tem.2023.05.003

Abstract

Doxorubicin (Dox) is a highly potent chemotherapy drug. Despite its efficacy, Dox's clinical application is limited due to its association with significant complications, namely cardiotoxicity and the risk of heart failure. Recent intriguing findings by Ozcan et al. indicate that alternate-day fasting (ADF) significantly exacerbates the cardiotoxicity of Dox.

Keywords: alternate-day fasting; autophagy; cancer; cardiotoxicity; doxorubicin; ferroptosis.

MeSH terms

Antibiotics, Antineoplastic / adverse effects
Apoptosis
Cardiotoxicity* / drug therapy
Cardiotoxicity* / etiology
Doxorubicin / adverse effects
Fasting
Humans
Myocytes, Cardiac
Neoplasms* / complications
Neoplasms* / drug therapy

Substances

Antibiotics, Antineoplastic
Doxorubicin